JPMorgan Chase & Co. Purchases 761,349 Shares of Nkarta, Inc. (NASDAQ:NKTX)

JPMorgan Chase & Co. raised its position in Nkarta, Inc. (NASDAQ:NKTX) by 252.1% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,063,362 shares of the company’s stock after purchasing an additional 761,349 shares during the period. JPMorgan Chase & Co. owned approximately 1.51% of Nkarta worth $4,806,000 as of its most recent filing with the SEC.

Several other hedge funds also recently bought and sold shares of the company. Erste Asset Management GmbH acquired a new position in shares of Nkarta in the 3rd quarter valued at approximately $33,000. GAMMA Investing LLC increased its position in shares of Nkarta by 110.9% during the third quarter. GAMMA Investing LLC now owns 9,972 shares of the company’s stock worth $45,000 after acquiring an additional 5,243 shares in the last quarter. Forefront Analytics LLC bought a new stake in Nkarta in the 2nd quarter valued at $70,000. Intech Investment Management LLC bought a new stake in Nkarta in the 3rd quarter valued at $74,000. Finally, SG Americas Securities LLC bought a new position in Nkarta during the 3rd quarter worth about $93,000. 80.54% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts have recently commented on the company. Mizuho cut their price target on Nkarta from $20.00 to $16.00 and set an “outperform” rating on the stock in a report on Thursday, November 21st. HC Wainwright cut their target price on Nkarta from $22.00 to $18.00 and set a “buy” rating on the stock in a research note on Monday, November 11th. Rodman & Renshaw started coverage on shares of Nkarta in a research note on Wednesday, October 9th. They set a “buy” rating and a $14.00 price target for the company. RODMAN&RENSHAW raised shares of Nkarta to a “strong-buy” rating in a research report on Wednesday, October 9th. Finally, Needham & Company LLC reduced their target price on shares of Nkarta from $13.00 to $11.00 and set a “buy” rating for the company in a report on Friday, November 8th. Five research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Nkarta has an average rating of “Buy” and a consensus target price of $15.00.

Insider Activity at Nkarta

In other Nkarta news, CEO Paul J. Hastings sold 17,378 shares of the stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $2.20, for a total value of $38,231.60. Following the completion of the sale, the chief executive officer now owns 319,859 shares in the company, valued at $703,689.80. This trade represents a 5.15 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 8.70% of the stock is owned by company insiders.

Nkarta Stock Down 0.8 %

NASDAQ:NKTX opened at $2.47 on Friday. Nkarta, Inc. has a twelve month low of $2.08 and a twelve month high of $16.24. The firm has a market capitalization of $174.31 million, a price-to-earnings ratio of -1.31 and a beta of 0.85. The stock’s 50 day moving average price is $2.54 and its two-hundred day moving average price is $4.21.

Nkarta Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.